Blood-based diagnostics of traumatic brain injuries

Traumatic brain injury is a major health and socioeconomic problem that affects all societies. However, traditional approaches to the classification of clinical severity are the subject of debate and are being supplemented with structural and functional neuroimaging, as the need for biomarkers that reflect elements of the pathogenetic process is widely recognized. Basic science research and developments in the field of proteomics have greatly advanced our knowledge of the mechanisms involved in damage and have led to the discovery and rapid detection of new biomarkers that were not available previously. However, translating this research for patients’ benefits remains a challenge. In this article, we summarize new developments, current knowledge and controversies, focusing on the potential role of these biomarkers as diagnostic, prognostic and monitoring tools of brain-injured patients.

[1]  Lai-Kwan Chau,et al.  Detection of antinuclear antibodies by a colloidal gold modified optical fiber: comparison with ELISA , 2007, Analytical and Bioanalytical Chemistry.

[2]  Li Chen,et al.  Evidence for an Interaction between Ubiquitin-Conjugating Enzymes and the 26S Proteasome , 2000, Molecular and Cellular Biology.

[3]  B. Pike,et al.  Temporal relationships between de novo protein synthesis, calpain and caspase 3‐like protease activation, and DNA fragmentation during apoptosis in septo‐hippocampal cultures , 1998, Journal of neuroscience research.

[4]  D. Brenner,et al.  Computed tomography--an increasing source of radiation exposure. , 2007, The New England journal of medicine.

[5]  H. Soininen,et al.  Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease , 2000, Neuroscience Letters.

[6]  R. Talanian,et al.  Simultaneous Degradation of αII- and βII-Spectrin by Caspase 3 (CPP32) in Apoptotic Cells* , 1998, The Journal of Biological Chemistry.

[7]  J. Simard,et al.  Glial fibrillary acidic protein is highly correlated with brain injury. , 2008, The Journal of trauma.

[8]  Ming Cheng Liu,et al.  Proteomic identification of biomarkers of traumatic brain injury , 2005, Expert review of proteomics.

[9]  J. Barth,et al.  Disability following head injury. , 1993, Current opinion in neurology.

[10]  Ming Liu,et al.  Calpain in the CNS: From Synaptic Function to Neurotoxicity , 2008, Science Signaling.

[11]  Frank Davis,et al.  Label-Free Immunochemistry Approach to Detect and Identity Antibiotics in Milk , 2010, Pediatric Research.

[12]  M. Wald,et al.  Traumatic brain injury in the United States; emergency department visits, hospitalizations, and deaths, 2002-2006 , 2010 .

[13]  A. Gabrielli,et al.  Use of biomarkers for diagnosis and management of traumatic brain injury patients. , 2008, Expert opinion on medical diagnostics.

[14]  V. Seifert,et al.  Correlation of Computed Tomography Findings and Serum Brain Damage Markers Following Severe Head Injury , 1998, Acta Neurochirurgica.

[15]  R. Neumar,et al.  Proteins released from degenerating neurons are surrogate markers for acute brain damage , 2004, Neurobiology of Disease.

[16]  Juan Lu,et al.  Prognostic value of secondary insults in traumatic brain injury: results from the IMPACT study. , 2007, Journal of neurotrauma.

[17]  F. Tortella,et al.  Detection of protein biomarkers using high-throughput immunoblotting following focal ischemic or penetrating ballistic-like brain injuries in rats , 2008, Brain injury.

[18]  Malmqvist,et al.  Epitope Mapping by Label-Free Biomolecular Interaction Analysis , 1996, Methods.

[19]  L. Mascia,et al.  Relationship of neuron specific enolase and protein S-100 concentrations in systemic and jugular venous serum to injury severity and outcome after traumatic brain injury. , 1998, Acta neurochirurgica. Supplement.

[20]  A. Marmarou,et al.  Outcome after severe head injury. Relationship to mass lesions, diffuse injury, and ICP course in pediatric and adult patients. , 1987, Journal of neurosurgery.

[21]  A. Raabe,et al.  Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. , 2004, The Journal of trauma.

[22]  P. Kochanek,et al.  Identification of Inflicted Traumatic Brain Injury in Well-Appearing Infants Using Serum and Cerebrospinal Markers: A Possible Screening Tool , 2006, Pediatrics.

[23]  J. Humphrey,et al.  Cancer Drug Discovery and Development , 2003 .

[24]  R. Anderson,et al.  High serum S100B levels for trauma patients without head injuries. , 2001, Neurosurgery.

[25]  J. Soustiel,et al.  Diffuse axonal injury: analysis of 100 patients with radiological signs. , 1990, Neurosurgery.

[26]  R. Hayes,et al.  Rapid discovery of putative protein biomarkers of traumatic brain injury by SDS-PAGE-capillary liquid chromatography-tandem mass spectrometry. , 2005, Journal of neurotrauma.

[27]  D. Marion,et al.  Problems with initial Glasgow Coma Scale assessment caused by prehospital treatment of patients with head injuries: results of a national survey. , 1994, The Journal of trauma.

[28]  V. Seifert,et al.  Serum S-100B protein in severe head injury. , 2000, Neurosurgery.

[29]  Shalini Prasad,et al.  Nanomonitors: Electrical immunoassays for protein biomarker profiling , 2008 .

[30]  J. Ghajar.  Traumatic brain injury , 2000, The Lancet.

[31]  R. Tufano,et al.  S100B Is Not a Reliable Prognostic Index in Paediatric TBI , 2007, Pediatric Neurosurgery.

[32]  A. Brown,et al.  Future developments in chest pain diagnosis and management. , 2010, The Medical clinics of North America.

[33]  F. Tortella,et al.  Ubiquitin C‐terminal hydrolase‐L1 as a biomarker for ischemic and traumatic brain injury in rats , 2010, The European journal of neuroscience.

[34]  Chaoqing Dong,et al.  Highly sensitive homogenous immunoassay of cancer biomarker using silver nanoparticles enhanced fluorescence correlation spectroscopy. , 2010, Talanta.

[35]  C. Alling,et al.  Controversial significance of early S100B levels after cardiac surgery , 2004, BMC neurology.

[36]  F. Tortella,et al.  Comparing calpain- and caspase-3-mediated degradation patterns in traumatic brain injury by differential proteome analysis. , 2006, The Biochemical journal.

[37]  J. Rossier,et al.  Identification of brain cell death associated proteins in human post-mortem cerebrospinal fluid. , 2006, Journal of proteome research.

[38]  Hanna Radecka,et al.  Comparison of electrochemical immunosensors based on gold nano materials and immunoblot techniques for detection of histidine-tagged proteins in culture medium. , 2008, Biosensors & bioelectronics.

[39]  Harlan M Krumholz,et al.  Exposure to low-dose ionizing radiation from medical imaging procedures. , 2009, The New England journal of medicine.

[40]  R. Grossman,et al.  Acetylcholine Metabolism in Intracranial and Lumbar Cerebrospinal Fluid and in Blood , 1980 .

[41]  B. Giordani,et al.  Disability caused by minor head injury. , 1981, Neurosurgery.

[42]  T. Soukka,et al.  Particulate and soluble Eu(III)-chelates as donor labels in homogeneous fluorescence resonance energy transfer based immunoassay. , 2008, Analytica chimica acta.

[43]  M. Badea,et al.  Antibody-based methods for surfactant screening , 2001, Fresenius' Journal of Analytical Chemistry.

[44]  U. Müller.  Protein detection using biobarcodes. , 2006, Molecular bioSystems.

[45]  Manfred Schmitt,et al.  Analytical Aspects of Biomarker Immunoassays in Cancer Research , 2006 .

[46]  Zhengping Li,et al.  Homogeneous immunoassay based on aggregation of antibody-functionalized gold nanoparticles coupled with light scattering detection. , 2008, Talanta.

[47]  V. Seifert,et al.  Serum markers of brain damage and outcome prediction in patients after severe head injury. , 1999, British journal of neurosurgery.

[48]  S. Robinson,et al.  The effect of acetylcholine depletion on behavior following traumatic brain injury , 1990, Brain Research.

[49]  G. Manley,et al.  Influence of data resolution and interpolation method on assessment of secondary brain insults in neurocritical care , 2005, Physiological measurement.

[50]  P. Englebienne.  Immune and Receptor Assays in Theory and Practice , 1999 .

[51]  A. Gómez-Hens,et al.  Homogeneous immunoassay for soy protein determination in food samples using gold nanoparticles as labels and light scattering detection. , 2009, Analytica chimica acta.

[52]  C. Woertgen,et al.  High serum S100B levels for trauma patients without head injuries. , 2001, Neurosurgery.

[53]  S. F. Carroll,et al.  Patterns of alcohol and drug abuse in an urban trauma center: the increasing role of cocaine abuse. , 1989, The Journal of trauma.

[54]  T. Nick,et al.  Long‐Term Neuropsychological Outcome After Traumatic Brain Injury , 2001, The Journal of head trauma rehabilitation.

[55]  M. Eichelberger,et al.  Interrogation of phosphor-specific interaction on a high-throughput label-free optical biosensor system–Epic® system , 2009, Journal of receptor and signal transduction research.

[56]  R. Rudick,et al.  Quantification of Axonal Damage in Traumatic Brain Injury , 1999, Journal of neurochemistry.

[57]  M. Wiesmann,et al.  Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. , 1999, Clinical chemistry.

[58]  Kathryn Saatman,et al.  Application of proteomics technology to the field of neurotrauma. , 2003, Journal of neurotrauma.

[59]  B. Romner,et al.  Traumatic brain damage: serum S-100 protein measurements related to neuroradiological findings. , 2000, Journal of neurotrauma.

[60]  A. Gabrielli,et al.  alphaII-Spectrin breakdown product cerebrospinal fluid exposure metrics suggest differences in cellular injury mechanisms after severe traumatic brain injury. , 2009, Journal of neurotrauma.

[61]  A. Gabrielli,et al.  αII-spectrin breakdown products (SBDPs): diagnosis and outcome in severe traumatic brain injury patients. , 2010, Journal of neurotrauma.

[62]  R. J. Block.  Proteins of the Nervous System , 1937, The Yale journal of biology and medicine.

[63]  C. Shah,et al.  Applications for the new electrochemiluminescent (ECL) and biosensor technologies. , 1999, Developments in biological standardization.

[64]  R. Hayes,et al.  A multidimensional differential proteomic platform using dual-phase ion-exchange chromatography-polyacrylamide gel electrophoresis/reversed-phase liquid chromatography tandem mass spectrometry. , 2005, Analytical chemistry.

[65]  J. Corrigan.  Substance abuse as a mediating factor in outcome from traumatic brain injury. , 1995, Archives of physical medicine and rehabilitation.

[66]  A. Gabrielli,et al.  Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury* , 2010, Critical care medicine.

[67]  A. Brawanski,et al.  S-100 serum levels after minor and major head injury. , 1998, The Journal of trauma.

[68]  J. Fernandes,et al.  LACTATE AS ENERGY SOURCE FOR BRAIN IN GLUCOSE-6-PHOSPHATASE DEFICIENT CHILD , 1982, The Lancet.

[69]  S. Kesler,et al.  SPECT, MR and quantitative MR imaging: correlates with neuropsychological and psychological outcome in traumatic brain injury. , 2000, Brain injury.

[70]  Kevin K. W Wang,et al.  Calpain and caspase: can you tell the difference? , 2000, Trends in Neurosciences.

[71]  G. Citerio,et al.  Inaccurate early assessment of neurological severity in head injury. , 2004, Journal of neurotrauma.

[72]  Eileen Maloney,et al.  A panel of neuron-enriched proteins as markers for traumatic brain injury in humans. , 2009, Journal of neurotrauma.

[73]  M. Wunderlich,et al.  Protein S-100B and neuron specific enolase as early neurobiochemical markers of the severity of traumatic brain injury. , 1999, Restorative neurology and neuroscience.

[74]  Increased levels of serum S100B protein in critically ill patients without brain injury , 2005, Shock.

[75]  T. Kaneko,et al.  Serum glial fibrillary acidic protein is a highly specific biomarker for traumatic brain injury in humans compared with S-100B and neuron-specific enolase. , 2010, The Journal of trauma.

[76]  B. Giordani,et al.  Neuropsychological sequelae of minor head injury. , 1983, Neurosurgery.

[77]  T. Beems,et al.  Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury , 2004, Neurology.

[78]  F. Tortella,et al.  Accumulation of Calpain and Caspase-3 Proteolytic Fragments of Brain-Derived αII-Spectrin in Cerebral Spinal Fluid after Middle Cerebral Artery Occlusion in Rats , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[79]  R. Cantu,et al.  Second-impact syndrome. , 1998, Clinics in sports medicine.

[80]  M A Foulkes,et al.  The role of secondary brain injury in determining outcome from severe head injury. , 1993, The Journal of trauma.

[81]  Neeraj,et al.  Digital Commons@Becker Digital Commons@Becker Classification of traumatic brain injury for targeted therapies Classification of traumatic brain injury for targeted therapies Classification of Traumatic Brain Injury for Targeted Therapies , 2008 .

[82]  T. Yoshizumi,et al.  Radiologic and nuclear medicine studies in the United States and worldwide: frequency, radiation dose, and comparison with other radiation sources--1950-2007. , 2009, Radiology.

[83]  Thomas B Cole,et al.  Global road safety crisis remedy sought: 1.2 million killed, 50 million injured annually. , 2004, JAMA.

[84]  A. Brawanski,et al.  Comparison of clinical, radiologic, and serum marker as prognostic factors after severe head injury. , 1999, The Journal of trauma.

[85]  J. Langlois,et al.  Traumatic brain injury in the United States; emergency department visits, hospitalizations, and deaths , 2006 .

[86]  L. Eng,et al.  Glial Fibrillary Acidic Protein: GFAP-Thirty-One Years (1969–2000) , 2000, Neurochemical Research.

[87]  D. Thomas,et al.  Radioimmunoassay of human myelin basic protein in tissue extract, cerebrospinal fluid and serum and its clinical application to patients with head injury. , 1978, Clinica chimica acta; international journal of clinical chemistry.

[88]  D. Thomas,et al.  SERUM-MYELIN-BASIC-PROTEIN ASSAY IN DIAGNOSIS AND PROGNOSIS OF PATIENTS WITH HEAD INJURY , 1978, The Lancet.

[89]  B. Romner,et al.  Biochemical serum markers of traumatic brain injury. , 2002, The Journal of trauma.

[90]  A. Brawanski,et al.  Comparison of serial S-100 and NSE serum measurements after severe head injury , 2005, Acta Neurochirurgica.

[91]  J. J. Buckley,et al.  Report of Three Cases , 1962 .

[92]  J. Falgueyret,et al.  Development of a homogeneous immunoassay for the detection of angiotensin I in plasma using AlphaLISA acceptor beads technology. , 2009, Analytical biochemistry.

[93]  S. Wisniewski,et al.  Increases in bcl-2 protein in cerebrospinal fluid and evidence for programmed cell death in infants and children after severe traumatic brain injury. , 2000, The Journal of pediatrics.

[94]  Jeremy J. Flint,et al.  Accumulation of non‐erythroid αII‐spectrin and calpain‐cleaved αII‐spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats , 2001 .

[95]  B. Rowlands,et al.  Neuron-specific enolase as an aid to outcome prediction in head injury. , 1996, British journal of neurosurgery.

[96]  R. Hayes,et al.  A novel marker for traumatic brain injury: CSF alphaII-spectrin breakdown product levels. , 2004, Journal of neurotrauma.

[97]  M. Leite,et al.  Biological and methodological features of the measurement of S100B, a putative marker of brain injury. , 2008, Clinical biochemistry.

[98]  D. Schmechel,et al.  Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. , 1987, Annual review of neuroscience.

[99]  Rachel P Berger,et al.  Biomarkers of primary and evolving damage in traumatic and ischemic brain injury: diagnosis, prognosis, probing mechanisms, and therapeutic decision making , 2008, Current opinion in critical care.

[100]  H S Levin,et al.  Lack of effect of induction of hypothermia after acute brain injury. , 2001, The New England journal of medicine.

[101]  J. Brisman,et al.  Reliability of S100B in predicting severity of central nervous system injury , 2007, Neurocritical care.

[102]  W. Mauritz,et al.  NONSPECIFIC INCREASE OF SYSTEMIC NEURON-SPECIFIC ENOLASE AFTER TRAUMA: CLINICAL AND EXPERIMENTAL FINDINGS , 2005, Shock.

[103]  G. Murray,et al.  The value of the "worst" computed tomographic scan in clinical studies of moderate and severe head injury. European Brain Injury Consortium. , 2000, Neurosurgery.

[104]  E. Leznik,et al.  The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders. , 2007, Drug news & perspectives.

[105]  C. Robertson,et al.  Clinical Significance of αII-Spectrin Breakdown Products in Cerebrospinal Fluid after Severe Traumatic Brain Injury , 2007 .

[106]  P. Kochanek,et al.  Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. , 2005, Journal of neurosurgery.

[107]  F. Tortella,et al.  Novel Differential Neuroproteomics Analysis of Traumatic Brain Injury in Rats* , 2006, Molecular & Cellular Proteomics.

[108]  E. Shooter,et al.  Proteins of the nervous system. , 1971, Annual review of biochemistry.

[109]  Tero Soukka,et al.  Homogeneous assay technology based on upconverting phosphors. , 2005, Analytical chemistry.

[110]  M. Verbeek,et al.  Measurement of glial fibrillary acidic protein in blood: an analytical method. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[111]  I. Zagon,et al.  Brain spectrin(240/235) and brain spectrin(240/235E): two distinct spectrin subtypes with different locations within mammalian neural cells , 1986, The Journal of cell biology.

[112]  J. Wood.  Neurobiology of Cerebrospinal Fluid 1 , 2012, Springer US.

[113]  Sean M. Grady,et al.  Clinical trials in head injury. , 2002, Neurological research.

[114]  R. Clark,et al.  Gel-Based Hippocampal Proteomic Analysis 2 Weeks following Traumatic Brain Injury to Immature Rats Using Controlled Cortical Impact , 2006, Developmental Neuroscience.

[115]  H. Xiong,et al.  [Pathophysiological alterations in cultured astrocytes exposed to hypoxia/reoxygenation]. , 2000, Sheng li ke xue jin zhan [Progress in physiology].

[116]  J. Vanderhaeghen,et al.  An acidic protein isolated from fibrous astrocytes. , 1971, Brain research.

[117]  T. Ohwada,et al.  Diagnostic significance of serum neuron-specific enolase and myelin basic protein assay in patients with acute head injury. , 1995, Surgical neurology.

[118]  V. Seifert,et al.  Fatal secondary increase in serum S-100B protein after severe head injury. Report of three cases. , 1999, Journal of neurosurgery.

[119]  H. Indyk,et al.  Direct optical biosensor analysis of folate-binding protein in milk. , 2004, Journal of agricultural and food chemistry.

[120]  J. Kepes,et al.  Suggested pathological basis of "redundant nerve root syndrome" of the cauda equina. , 1980, Neurosurgery.

[121]  Ye Fang,et al.  Label-free cell-based assays for GPCR screening. , 2008, Combinatorial chemistry & high throughput screening.

[122]  S. Mackenzie,et al.  Should the pre‐sedation Glasgow Coma Scale value be used when calculating Acute Physiology and Chronic Health Evaluation scores for sedated patients? , 2000, Critical care medicine.

[123]  Viswanath Devanarayan,et al.  Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.

[124]  S. Robinson,et al.  Hypothermia blunts acetylcholine increase in CSF of traumatically brain injured rats. , 1993, Molecular and chemical neuropathology.

[125]  Xuemin Zhang,et al.  Expressive proteomics profile changes of injured human brain cortex due to acute brain trauma , 2009, Brain injury.

[126]  S. Hanash,et al.  Comparative study of SPR and ELISA methods based on analysis of CD166/ALCAM levels in cancer and control human sera. , 2009, Biosensors & bioelectronics.

[127]  A. Raabe,et al.  GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. , 2004, Journal of neurotrauma.